What question did this study set out to answer?

To assess pharmacologic treatment patterns overall and across combined hormone receptor and HER2 subtypes among women with metastatic breast cancer in Western Europe.

May 16, 2012Current Medical Research and Opinion

Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe

View Full Paper

Ask AI

Bookmark

To assess pharmacologic treatment patterns overall and across combined hormone receptor and HER2 subtypes among women with metastatic breast cancer in Western Europe.
Analyzed cross-sectional data from the LifeLink Oncology Analyzer Database comprising N=4670 women with metastatic breast cancer from France, Germany, Italy, Spain, and the UK.
Evaluated most recent pharmacologic treatments (chemotherapy, endocrine therapy, HER2-targeted therapy, or others) stratified descriptively by combined HR/HER2 tumor receptor status and patient age (≤55 vs. >55 years).
Among 4070 women with known receptor status, the HR+/HER2- subtype was most common (53.5%) and HR-/HER2+ was least common (12.6%).
Among 4060 women with documented therapies, chemotherapy was administered to 59%, endocrine therapy to 33%, and HER2-targeted therapy to 15%.
Patients aged ≤55 years were more likely to receive chemotherapy and less likely to receive endocrine therapy compared with patients aged >55 years.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cross-sectional study reveals treatment patterns vary by receptor status and age in metastatic breast cancer, highlighting chemotherapy as the primary modality.

Cite This Study

Gao et al. (2012) studied this question.

synapsesocial.com/papers/6a72a56e3ce530166bc35b49 https://doi.org/10.1185/03007995.2012.694364

View Full Paper

Ask AI

Bookmark

Implication

Cross-sectional study reveals treatment patterns vary by receptor status and age in metastatic breast cancer, highlighting chemotherapy as the primary modality.

Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe

Key Points

Discussion

Implication

Cite This Study

Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading